NEW YORK – Qorvo Biotechnologies announced on Monday that it has received a $4.1 million award from the National Institutes of Health's Rapid Acceleration of Diagnostics initiative to advance a SARS-CoV-2 and influenza combo test and a pooling application for its SARS-CoV-2 antigen test.
The money will be used to advance clinical trials and market launch of a SARS-CoV-2/Flu Combo Assay and its SARS-CoV-2 antigen test for pooled testing. Both tests leverage the Qorvo Omnia diagnostic test platform, which uses high frequency bulk acoustic wave sensors to measure antigens. The combo test will detect and differentiate between SARS-CoV-2, influenza A, and Influenza B using a single sample in about 20 minutes, the firm said in a statement. The antigen pooling application will allow up to six samples to be processed together and tested at the same time.
Greensboro, North Carolina-based Qorvo was previously awarded $24.4 million from the NIH for the production and market launch of its Qorvo Omnia platform. The firm received Emergency Use Authorization from the US Food and Drug Administration for its Qorvo Omnia SARS-CoV-2 Antigen Test in April.